NSE/JBCHEPHARM

JBCHEPHARMJB Chemicals & Pharmaceuticals

Healthcare · NSE

₹1,998+1.16%

52-wk low52-WEEK RANGE52-wk high

₹1,504.4+32.8% from low ·-6.6% from high₹2,138.6

Price chart · 1M–10Y · daily-close

NSE bhavcopy + 10Y historical

JBCHEPHARM+29.53% · 1Y

Range high ₹2,195Range low ₹1,494.8Latest ₹1,998252 bars · daily-close · NSE bhavcopy + 10Y history

HealthcareMidcap

Stock scorecard

Auto-computed from latest ratios + sector context · not a buy/sell signal

Composite50/100

Performance

—

Not enough price history to score.

Valuation

High

Looks expensive vs the sector.

· P/E 41.9 close to sector median 37.8
· P/B 8.19 above sector median

Growth

Medium

Steady but not standout growth.

· Revenue YoY +12.4%
· Profit YoY +19.4%

Profitability

High

Showing good signs of profitability & efficiency.

· Net margin 16.8% — strong pricing power

DVM composite · Durability · Valuation · Momentum

Trendlyne-style 3-axis composite · all drivers shown below · not a buy/sell signal

CompositeB(67/100)

Durability

A+

100/100

Financially resilient — strong quality + solvency profile.

Show 1 drivers

Debt/Equity0.01 (100pt)

Valuation

42/100

Trading at a premium — growth must keep delivering to justify.

Show 4 drivers

P/E vs sector (41.9 / 37.8)111% (54pt)
P/B8.19 (40pt)
Dividend yield1.27% (32pt)
EV/EBITDA27.1 (26pt)

Momentum

58/100

Constructive setup — momentum building, not extended.

Show 4 drivers

DMA-trend alignmentsideways (50pt)
RSI (14)47.2 (60pt)
Price vs 200-DMA+10.2% (80pt)
MACD regimebearish (30pt)

Valuation positioning

Current ratio vs sector peer distribution

P/E (TTM)41.90

FAIR

CheapestP/E 41.9 near sector median.Most expensive

P/B8.19

OVERVALUED

CheapestP/B 8.19 at 75th %ile of sector.Most expensive

EV/EBITDA27.08

OVERVALUED

Monthly seasonality

Avg monthly return over 10 years · historical — not a forecast

Best: Jul +5.92% · Worst: Nov 0.03%

Jan

+1.1%

50% win

Feb

+0.7%

50% win

Mar

+2.4%

60% win

Apr

+4.4%

60% win

May

+1.9%

60% win

Jun

+0.8%

Monthly return distribution

Distribution of 120 monthly returns

Mean

+2.64%

Median

+2.48%

Std dev

7.77%

Best

+28.3%

Worst

-14.1%

% positive

61%

SWOT analysis

Auto-derived from ratios + sector context + forensics · research only, not a recommendation

STRENGTHS · 2

Lean balance sheet (D/E 0.01)
Low leverage means earnings are less sensitive to rate cycles
Strong net margin (16.8%)
High margin indicates pricing power + operating efficiency

WEAKNESSES · 0

No material weaknesses flag from the numbers

OPPORTUNITIES · 0

No strong near-term catalysts visible

THREATS · 0

No immediate threats from the data

RETURNS · DAILY-CLOSE BASED

3Y+ shown as CAGR

+1.2%

-0.4%

-5.8%

+4.6%

+18.2%

+31.2%

+26.2%

+26.6%

10Y

+31.9%

Peer	Last close	1Y change	Mcap ₹Cr	P/E	P/B	ROE	D/E	Rev YoY
JBCHEPHARMTHIS JB Chemicals & Pharmaceuticals Limited	₹1,998	+20.5%	31,987	41.9	8.19	—	0.01	+12.4%
DIVISLAB Divi's Laboratories Limited	₹6,229	+5.7%	1,66,714	67.2	10.81	16.1%	0.01	+12.3%
APOLLOHOSP Apollo Hospitals Enterprise Limited	₹7,699	+7.8%	1,10,096	61.0	12.11	19.8%	0.84	+17.2%
LUPIN Lupin Limited	₹2,326.1	+15.8%	1,06,756	23.0	5.43	—	0.32	+13.5%
DRREDDY Dr. Reddy's Laboratories Limited	₹1,235.7	+5.0%	1,02,626	18.2	2.76	16.1%	0.18	+4.4%
CIPLA Cipla Limited	₹1,240.8	-17.9%	99,317	21.9	3.02	13.8%	0.01	0.0%
MAXHEALTH Max Healthcare Institute Limited	₹1,007.65	-6.1%	98,448	69.7	9.85	—	0.33	+30.0%
MANKIND Mankind Pharma Limited	₹2,125	-17.9%	87,619	49.2	5.73	—	0.54	+18.1%
AUROPHARMA Aurobindo Pharma Limited	₹1,386	+15.4%	80,209	23.0	2.29	9.9%	0.22	+9.4%

ASK AXEL

Dig deeper into JBCHEPHARM

Axel can fetch latest news, peer valuation, consensus estimates, insider activity, and concall commentary for JBCHEPHARM — all in one sourced reply.

Ask free in chat

Run these tools on JBCHEPHARM

Historical return →

"If I had bought JBCHEPHARM in year X"

Rolling returns →

Worst/best 1/3/5/7/10-yr windows

Buy-the-dip backtester →

Dip-buying vs SIP on JBCHEPHARM

Brokerage + charges →

All-in cost for trading JBCHEPHARM

Research tool · not investment advice.

Axel Markets is an information + analytics product. We are not a SEBI-registered Research Analyst (RA) or Investment Adviser (IA). Nothing on this page is a buy, sell, or hold recommendation. Past performance is not indicative of future returns. Verify all data against the authoritative source (NSE, BSE, AMFI, SEBI, company RHP / factsheet) before acting. Daily OHLCV sourced primarily from our NSE bhavcopy ingest (public sec_bhavdata_full CSV), with Stooq as a fallback for historical gaps. Split + bonus adjusted. Excludes dividends. Not a recommendation. Past performance does not predict future returns. For authoritative live quotes see NSE / BSE directly.

Quarter	EPS estimate	EPS actual	Surprise %
-1q	12.50	12.45	-0.4%
-2q	12.90	13.08	+1.4%
-3q	13.60	12.75	-6.2%
-4q	8.83	9.17	+3.8%

Date	Amount
2026-02-11	₹12.70
2025-07-30	₹7.00
2025-02-07	₹8.50
2024-08-14	₹6.75
2024-02-16	₹5.50
2023-08-17	₹4.63
2023-02-17	₹4.25
2022-08-12	₹4.00
2022-02-23	₹4.25
2021-09-01	₹4.00
2021-02-18	₹4.25
2020-09-22	₹0.50
2020-03-03	₹5.00
2019-08-14	₹2.50
2018-08-27	₹1.00
2017-09-11	₹0.50
2016-08-11	₹0.25

JBCHEPHARMJB Chemicals & Pharmaceuticals

Price chart · 1M–10Y · daily-close

Stock scorecard

DVM composite · Durability · Valuation · Momentum

Valuation positioning

Monthly seasonality

Monthly return distribution

SWOT analysis

Fundamentals

Pros and cons

Sector-relative context

Peer comparison · Healthcare

Ask Axel about JBCHEPHARM

Recent news

Dig deeper into JBCHEPHARM

Run these tools on JBCHEPHARM

Technical snapshot

Earnings history + surprises

Dividends + splits history

Recent news

Stock scorecard

SWOT analysis

Fundamentals

Pros and cons

Sector-relative context

DVM composite · Durability · Valuation · Momentum

Valuation positioning

Monthly seasonality

Monthly return distribution

Peer comparison · Healthcare